Evidence map›Paper›PMID 37013051›Full record

ArticleGenes & diseases2023

Systematic comparison of experimental and human obstructive cholestasis reveals conservation of canonical pathway activation and biomarkers relevant for cholestatic liver disease.

Eva Gijbels, Kevin De Muynck, Bart Vanderborght, Tim Meese, Filip Van Nieuwerburgh, Aude Vanlander, Frederik Berrevoet, Bart Hendrikx, Anne Hoorens, Hans Van Vlierberghe and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Genes & diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Eva GijbelsDepartment of Pharmaceutical and Pharmacological Sciences, Vrije Universiteit Brussel, 1090 Brussels, Belgium.
Kevin De MuynckGut-Liver Immunopharmacology Unit, Basic and Applied Medical Sciences; Liver Research Centre Ghent; Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium.
Bart VanderborghtHepatology Research Unit, Internal Medicine and Paediatrics; Liver Research Centre Ghent; Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium.
Tim MeeseLab of Pharmaceutical Biotechnology, Ghent University, 9000 Ghent, Belgium.
Filip Van NieuwerburghLab of Pharmaceutical Biotechnology, Ghent University, 9000 Ghent, Belgium.
Aude VanlanderDepartment of HPB Surgery and Liver Transplantation, Ghent University Hospital, 9000 Ghent, Belgium.
Frederik BerrevoetDepartment of HPB Surgery and Liver Transplantation, Ghent University Hospital, 9000 Ghent, Belgium.
Bart HendrikxDepartment of HPB Surgery and Liver Transplantation, Ghent University Hospital, 9000 Ghent, Belgium.
Anne HoorensDepartment of Pathology, Ghent University Hospital, 9000 Ghent, Belgium.
Hans Van VlierbergheHepatology Research Unit, Internal Medicine and Paediatrics; Liver Research Centre Ghent; Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium.
Mathieu VinkenDepartment of Pharmaceutical and Pharmacological Sciences, Vrije Universiteit Brussel, 1090 Brussels, Belgium.
Lindsey DevisscherGut-Liver Immunopharmacology Unit, Basic and Applied Medical Sciences; Liver Research Centre Ghent; Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID37013051
PMCPMC10066269

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.